NovaSAID is a research company developing compounds that selectively inhibit PGE2 synthesis, for the treatment of diseases associated with inflammation, pain and fever.

Our goal is to develop a compound that selectively inhibits prostaglandin E synthase (mPGEs-1) and that has a superior side-effect profile compared to COX-2 inhibitors and traditional NSAIDs.

NovaSAID was founded in 2004 by Associate professor Per-Johan Jakobsson and Professor Ralf Morgenstern, who together with Professor Bengt Samuelsson discovered the enzyme mPGEs-1 in 1997. The company was a subsidiary to Actar until 2008 when it became independent with Karolinska Development Holding AB as the majority owner.

NovaSAID is situated at the Karolinska Institute Science Park, Stockholm, Sweden.